Low disease activity state in rheumatoid arthritis: Concepts and derivation of minimal disease activity

Clinical and Experimental Rheumatology

Volumn 24, Issue 6 SUPPL. 43, 2006, Pages

  Wells, George ^a   Boers, Maarten ^b   Tugwell, Peter ^a   Aletaha, Daniel ^c   Anderson, Jennifer ^c   Bombardier, Clair ^c   Brooks, Peter ^c   Dougados, Maxime ^c   Emery, Paul ^c   Felson, David ^c   Fransen, Jaap ^c   Furst, Dan ^c   Hazes, Mieke ^c   Johnson, Kent ^c   Kirwan, John ^c   Landewé, Robert ^c   Lassere, Marissa ^c   Michaud, Kaleb ^c   Shea, Beverley ^c   Suarez Almazor, Maria ^c   Silman, Alan ^c   Simon, Lee ^c   Smolen, Josef ^c   Strand, Vibeke ^c   van der Heijde, Desiree ^c   van Riel, Piet ^c   Wolfe, Fred ^c   more..

^a UNIVERSITY OF OTTAWA   (Canada)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

Low disease activity state; Minimal disease activity; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUAL VALIDITY; DISEASE ACTIVITY; DISEASE DURATION; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MINIMAL DISEASE ACTIVITY; NOMENCLATURE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; TREATMENT PLANNING; VALIDATION PROCESS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; PRACTICE GUIDELINES; REFERENCE VALUES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 33750741119     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Van der HEIJDE DM, van't HOF MA, van RIEL PL et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
2. BOERS M, TUGWELL P. FELSON DT et al.: World health organization and international league of associations for rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21: 86-9.
3. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
4. VAN GESTEL AM, PREVOO ML, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LB, VAN RIEL PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
5. BOERS M, BROOKS P, STRAND V, TUGWELL P: The OMERACT Filter for outcome measures in rheumatology. J Rheumatol 1998; 25: 198-9.
6. KIRWAN JR, CHAPUT DE SAINTONGE DM, JOYCE CR, CURREY HL: Clinical judgement analysis - practical application in rheumatoid arthritis. Br J Rheumatol 1983; 22: 18-23.
7. WELLS, GA, BOERS, M, SHEA B et al.: Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 2016-24.
8. WELLS G, BOERS M, SHEA B et al.: MCID/Low Disease Activity State Workshop: Low disease activity state in rheumatoid arthritis. J Rheumatol 2003; 30: 1110-1.
9. BOERS M, ANDERSON JJ, FELSON DT: Deriving an operational definition of low disease activity state in rheumatoid arthritis. J Rheumatol 2003; 30: 1112-4.
10. WELLS G, ANDERSON J, BOERS M et al.: MCID/Low disease activity state workshop: Summary, recommendations, and research agenda. J Rheumatol 2003; 30: 1115-8.
11. KIRWAN J, HEIBERG T, HEWLETT S et al.: Outcomes from the patient perspective workshop at OMERACT 6. J Rheumatol 2003; 30: 868-72.
12. KIRWAN JR, HEWLETT S, HEIBERG T et al.: Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol 2005; 32.
13. WOLFE F, MICHAUD K, PINCUS T, FURST D, AND KEYSTONE E: The DAS score is not suitable as the criterion for TNF initiation in the clinic: evidence of disagreement between physician and patient assessments and DAS scores. Arthritis Rheum 2004; 50 (Suppl.): S459 (abstract).
14. ALETAHA D, WARD MM, MACHOLD KPM, NELL VPK, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Submitted for publication.
15. WELLS G, BOERS M, SIMON L, STRAND V, TUGWELL P: Validation of minimal disease activity for rheumatoid arthritis. Arthritis Rheum 2005; 52 (Suppl.): S657 (abstract).
16. WELLS G, BOERS M, LI T, TUGWELL P: Validation of minimal disease activity for rheumatoid arthritis patients treated with the biologic therapy abatacept. Arthritis Rheum 2006; (abstract) (to be presented).
17. LANDEWE R, VAN DER HEIJDE D, VOSKUYL AE, BOERS M: Condensed 28-joint counts jeopardise the construct validity of DAS28-remission: a comparison with the original DAS. Arthritis Rheum 2004; 50 (Suppl.): S458 (abstract).